These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. scAAVengr, a transcriptome-based pipeline for quantitative ranking of engineered AAVs with single-cell resolution. Öztürk BE; Johnson ME; Kleyman M; Turunç S; He J; Jabalameli S; Xi Z; Visel M; Dufour VL; Iwabe S; Pompeo Marinho LFL; Aguirre GD; Sahel JA; Schaffer DV; Pfenning AR; Flannery JG; Beltran WA; Stauffer WR; Byrne LC Elife; 2021 Oct; 10():. PubMed ID: 34664552 [TBL] [Abstract][Full Text] [Related]
26. AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice. Liguore WA; Domire JS; Button D; Wang Y; Dufour BD; Srinivasan S; McBride JL Mol Ther; 2019 Nov; 27(11):2018-2037. PubMed ID: 31420242 [TBL] [Abstract][Full Text] [Related]
27. Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain. Matsuzaki Y; Konno A; Mochizuki R; Shinohara Y; Nitta K; Okada Y; Hirai H Neurosci Lett; 2018 Feb; 665():182-188. PubMed ID: 29175632 [TBL] [Abstract][Full Text] [Related]
28. Focused ultrasound-induced blood-brain barrier opening for non-viral, non-invasive, and targeted gene delivery. Lin CY; Hsieh HY; Pitt WG; Huang CY; Tseng IC; Yeh CK; Wei KC; Liu HL J Control Release; 2015 Aug; 212():1-9. PubMed ID: 26071631 [TBL] [Abstract][Full Text] [Related]
29. Focused Ultrasound-Mediated Disruption of the Blood-Brain Barrier for AAV9 Delivery in a Mouse Model of Huntington's Disease. Owusu-Yaw BS; Zhang Y; Garrett L; Yao A; Shing K; Batista AR; Sena-Esteves M; Upadhyay J; Kegel-Gleason K; Todd N Pharmaceutics; 2024 May; 16(6):. PubMed ID: 38931834 [TBL] [Abstract][Full Text] [Related]
30. Extracellular Vesicle-Encapsulated Adeno-Associated Viruses for Therapeutic Gene Delivery to the Heart. Li X; La Salvia S; Liang Y; Adamiak M; Kohlbrenner E; Jeong D; Chepurko E; Ceholski D; Lopez-Gordo E; Yoon S; Mathiyalagan P; Agarwal N; Jha D; Lodha S; Daaboul G; Phan A; Raisinghani N; Zhang S; Zangi L; Gonzalez-Kozlova E; Dubois N; Dogra N; Hajjar RJ; Sahoo S Circulation; 2023 Aug; 148(5):405-425. PubMed ID: 37409482 [TBL] [Abstract][Full Text] [Related]
31. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gray SJ; Nagabhushan Kalburgi S; McCown TJ; Jude Samulski R Gene Ther; 2013 Apr; 20(4):450-9. PubMed ID: 23303281 [TBL] [Abstract][Full Text] [Related]
32. Noninvasive focused ultrasound-mediated delivery of rAAV9-EGFP vectors for neuronal targeting in rats. Wang R; Li J Neuroimage; 2024 Jul; 294():120630. PubMed ID: 38740226 [TBL] [Abstract][Full Text] [Related]
33. A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency. Tordo J; O'Leary C; Antunes ASLM; Palomar N; Aldrin-Kirk P; Basche M; Bennett A; D'Souza Z; Gleitz H; Godwin A; Holley RJ; Parker H; Liao AY; Rouse P; Youshani AS; Dridi L; Martins C; Levade T; Stacey KB; Davis DM; Dyer A; Clément N; Björklund T; Ali RR; Agbandje-McKenna M; Rahim AA; Pshezhetsky A; Waddington SN; Linden RM; Bigger BW; Henckaerts E Brain; 2018 Jul; 141(7):2014-2031. PubMed ID: 29788236 [TBL] [Abstract][Full Text] [Related]
34. Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hinderer C; Katz N; Buza EL; Dyer C; Goode T; Bell P; Richman LK; Wilson JM Hum Gene Ther; 2018 Mar; 29(3):285-298. PubMed ID: 29378426 [TBL] [Abstract][Full Text] [Related]
35. One episode of low intensity aerobic exercise prior to systemic AAV9 administration augments transgene delivery to the heart and skeletal muscle. Pacak CA; Suzuki-Hatano S; Khadir F; Daugherty AL; Sriramvenugopal M; Gosiker BJ; Kang PB; Cade WT J Transl Med; 2023 Oct; 21(1):748. PubMed ID: 37875924 [TBL] [Abstract][Full Text] [Related]
36. Development of CNS tropic AAV1-like variants with reduced liver-targeting following systemic administration in mice. Drouyer M; Merjane J; Nazareth D; Knight M; Scott S; Liao SHY; Ginn SL; Zhu E; Alexander IE; Lisowski L Mol Ther; 2024 Mar; 32(3):818-836. PubMed ID: 38297833 [TBL] [Abstract][Full Text] [Related]
37. Transduction of the central nervous system after intracerebroventricular injection of adeno-associated viral vectors in neonatal and juvenile mice. Gholizadeh S; Tharmalingam S; Macaldaz ME; Hampson DR Hum Gene Ther Methods; 2013 Aug; 24(4):205-13. PubMed ID: 23808551 [TBL] [Abstract][Full Text] [Related]